Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00542971 · ClinicalTrials.gov registry record · Phase 1
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
NCT00542971: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00542971 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 78 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00542971, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
Study Summary
A primary goal of this clinical research study is to find the highest safe dose of sorafenib that can be given in combination with idarubicin and Ara-C for the treatment of acute myelogenous leukemia (AML) and high-risk, myelodysplastic syndrome (MDS). Once the highest safe dose is found, researchers will then try to learn if this combination treatment can help control AML and high-risk MDS in newly diagnosed patients. The safety of this treatment combination will also be studied.
Interventions
- DRUG Idarubicin
- DRUG Sorafenib
- DRUG Ara-C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2007-10 |
| Est. Completion | 2011-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00542971
The ClinicalTrials.gov registry entry for NCT00542971 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Idarubicin is the first listed.
NCT00542971 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00542971 about?
NCT00542971 is a clinical study titled "Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)". A primary goal of this clinical research study is to find the highest safe dose of sorafenib that can be given in combination with idarubicin and Ara-C for the treatment of acute myelogenous leukemia (AML) and high-risk, myelodysplastic syndrome (MDS). Once the highest safe dose is found, researche...
What is the current status of trial NCT00542971?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2007-10. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00542971?
The interventions under investigation include: Idarubicin (DRUG), Sorafenib (DRUG), Ara-C (DRUG).
Who is sponsoring clinical trial NCT00542971?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.